No Data Yet
Beam Therapeutics' stock has risen 58.7% over the last six months, driven by positive Phase I/II trial data for its sickle cell disease treatment, risto-cel.
Beam Therapeutics reported positive new data from its BEACON trial for risto-cel, a therapy for sickle cell disease, demonstrating significant clinical improvements. A preliminary valuation analysis suggests a potential $65 per share value for the company's lead assets, signaling renewed momentum.